Results 11 to 20 of about 13,189,470 (203)

Amphotericin B

Applied Microbiology and Biotechnology, 2005
Invasive fungal infections are a major cause of morbidity and mortality in immunodeficient individuals (such as AIDS patients) and in transplant recipients or tumor patients undergoing immunosuppressive chemotherapy.
Lemke, A., Kiderlen, A. F., Kayser, Oliver   +2 more
core   +4 more sources

Amphotericin B-Induced Encephalopathy

Pediatric Neurology Briefs, 1995
Three children with refractory leukemia treated by bone marrow transplantation at the Children’s National Medical Center, Washington, DC, developed encephalopathy, leukoencephalopathy, and parkinsonism after receiving high-dose amphotericin B for ...
J Gordon Millichap
doaj   +2 more sources

Black and white teas as potential agents to combine with amphotericin B and protect red blood cells from amphotericin B-mediated toxicity

Brazilian Journal of Biology, 2018
Amphotericin B is a fungicidal substance that is treatment of choice for most systemic fungal infections affecting immunocompromised patients. However, severe side effects have limited the utility of this drug.
V. M. Oliveira, N. M. Khalil, E. Carraro
doaj   +3 more sources

Amphotericin-B in dermatology

Indian Dermatology Online Journal, 2022
Akash Agarwal, Bikash R Kar
doaj   +3 more sources

Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis

Research and Reports in Tropical Medicine, 2019
Mohammad Reza Shirzadi1,21Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran; 2Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Science, Tehran, IranAbstract: The genus ...
Shirzadi MR
doaj   +1 more source

Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™ [PDF]

, 2011
Background: Despite advances in the treatment, the morbidity and mortality rate associated with invasive aspergillosis remains unacceptably high (70–90%) in immunocompromised patients.
Italia, Jagdishbhai L, Kumar, M N V Ravi, Warn, Peter, Sharp, Andrew, Carter, Katharine C   +4 more
core   +5 more sources

Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. [PDF]

, 2014
Cryptococcal meningoencephalitis is an urgent global health problem. Induction regimens using 14 days of amphotericin B deoxycholate (dAmB) are considered the standard of care but may not be suitable for resource-poor settings.
Sharp, Andrew D, Andrew D. Sharp, Julie A. Schwartz, Gregson, Lea, Howard, Susan J, Goodwin, Joanne, Susan J. Howard, Bill Moser, John R. Perfect, Müller, W, Sharp, AD, Joanne Goodwin, Moser, Bill, Walker, Catherine, Hope, William W, Lea Gregson, Hope, WW, Perfect, John R, Joanne Livermore, Werner Müller, Schwartz, JA, William W. Hope, Felton, Timothy; id_orcid, Timothy Felton, Catherine Walker, Livermore, J, Schwartz, Julie A, Gregson, L, Goodwin, J, Harrison, Thomas S, Livermore, Joanne, Howard, SJ, Felton, T, Harrison, TS, Walker, C, Perfect, JR, Thomas S. Harrison, Müller, Werner; id_orcid, Moser, B   +38 more
core   +1 more source

Liposomal amphotericin B—the past [PDF]

Journal of Antimicrobial Chemotherapy, 2022
Abstract The discovery of amphotericin B, a polyene antifungal compound, in the 1950s, and the formulation of this compound in a liposomal drug delivery system, has resulted in decades of use in systemic fungal infections. The use of liposomal amphotericin B formulation is referenced in many international guidelines for the treatment of ...
R J Brüggemann, G M Jensen, C Lass-Flörl   +2 more
openaire   +3 more sources

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India [PDF]

, 2011
Reports on treatment outcomes of visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied the efficacy of liposomal amphotericin B in VL-HIV coinfection.
Pece, Manuel, Flevaud, L., Mahajan, Raman, Remartinez, D., Das, Pradeeb, Verma, Neena, Kumar, Nawin, Remartinez, Daniel, M. Pece, Ferreyra, Cecilia, Mitra, G., G. Mitra, N. Verma, Ferreyra, C., Pandey, K., Das, P., van Griensven, Johan, K. Pandey, R. Kumar, R. Mahajan, Mahajan, R., Pandey, Krishna, Kumar, Ranjeet, Mitra, Gaurab, Pece, M., P. P. Palma, Verma, N., P. Das, Kumar, Pankaj, Kumar, N., C. Ferreyra, D. Remartinez, Kumar, P., N. Kumar, Sinha, Prabhat K, Kumar, R., P. K. Sinha, van Griensven, J., Palma, P. P., Sinha, P. K., P. Kumar, Flevaud, Laurence, Palma, Pedro Pablo, J. van Griensven, L. Flevaud   +44 more
core   +1 more source

Amphotericin B in the management of COVID-19 associated mucormycosis [PDF]

, 2023
Background: Amphotericin B is considered the drug of choice for primary treatment of mucormycosis. During second wave of COVID-19 pandemic there was severe scarcity of liposomal amphotericin B. This study aims to determine role of various formulations of
Premachandran, Architha M., Sheeja, Arunima, Shivalingaiah, Pruthvi R., Godse, Ashwini, Chandrashekar, Ravishankar, Pruthvi R. Shivalingaiah, Ashwini Godse, Ravishankar Chandrashekar, Arunima Sheeja, Architha M. Premachandran   +9 more
core   +1 more source